Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 5, 2010, Pages 2343-2350

  Reubi, Jean Claude ^a   Waser, Beatrice ^a   Cescato, Renzo ^a   Gloor, Beat ^b   Stettler, Christoph ^b   Christ, Emanuel ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R2 88; MONOCLONAL ANTIBODY UMB 1; OCTREOTIDE; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY SS B00; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; RADIOACTIVE IODINE; SOMATOSTATIN RECEPTOR;

ARTICLE; AUTORADIOGRAPHY; BILE DUCT TUMOR; BRONCHUS TUMOR; CANCER SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; EMBRYO; ENDOSOME; HEART METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERNALIZATION; LIVER METASTASIS; LOW DRUG DOSE; LYSOSOME; MESENTERY TUMOR; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PEROPERATIVE CARE; PREOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; CELL LINE; CELL MEMBRANE; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALIA;

ANTINEOPLASTIC AGENTS, HORMONAL; AUTORADIOGRAPHY; CELL LINE; CELL MEMBRANE; ENDOSOMES; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; KIDNEY; LYSOSOMES; NEUROENDOCRINE TUMORS; OCTREOTIDE; RECEPTORS, SOMATOSTATIN;

EID: 77952756362     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2487     Document Type: Article

References (35)

1. Lefkowitz RJ, Shenoy SK 2005 Transduction of receptor signals by β-arrestins. Science 308:512-517
2. Hanyaloglu AC, von Zastrow M 2008 Regulation of GPCRs by endocyticmembranetrafficking and its potential implications.Annu Rev Pharmacol Toxicol 48:537-568
3. Seachrist JL, Ferguson SS 2003 Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. Life Sci 74: 225-235
4. Claing A, Laporte SA, Caron MG, Lefkowitz RJ 2002 Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 66:61-79 (Pubitemid 34251168)
5. Mantyh PW, Allen CJ, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum AI, Vigna SR, Maggio JE 1995 Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc Natl Acad Sci USA 92: 2622-2626
6. Mantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum AI, Vigna SR, Maggio JE, Simone,DA 1995 Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268:1629-1632
7. Reubi JC 2003 Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
8. Bodei L, Paganelli G, Mariani G 2006 Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J Nucl Med 47:375-377 (Pubitemid 46768477)
9. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ 2009 Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 5:382-393
10. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP 2005 Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754-2762
11. Hofland LJ, Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47
12. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC 2006 Internalization of sst2, sst3 and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47:502-511
13. Liu Q, Cescato R, Dewi DA, Rivier J, Reubi JC, Schonbrunn A 2005 Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol 68:90-101
14. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR 2005 Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11:1136-1145
15. 99mTc: a preclinical study. J Med Chem 48:100-110
16. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC 2009 Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 50:936-941
17. Körner M, Eltschinger V, Waser B, Schonbrunn A, Reubi JC 2005 Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 29:1642-1651
18. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A 1998 Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 153:233-245 (Pubitemid 28317526)
19. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M 2007 Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172-1182
20. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L 2008 Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression:newprognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26:963-970
21. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S 2008 Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 93:4519-4524
22. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B 2004 Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966-973
23. Fiess H, Klempa I, Hermanek P, Sulkowski U, Uhl W, Beger HG, Buchler MW 1994 Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Germany. Digestion 55(Suppl 1):35-40 (Pubitemid 24020277)
24. Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW, Schonbrunn A 1999 Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. J Clin Endocrinol Metab 84:2942-2950
25. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A 2000 Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J Clin Endocrinol Metab 85:3882-3891
26. Reubi JC, Waser B, Schaer JC, Laissue JA 2001 Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836-846
27. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Höllt V, Schulz S 2004 Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 279:21374-21382
28. Mentlein R, Held-Feindt J, Krisch B 2001 Topology of the signal transduction of the G protein-coupled somatostatin receptor sst2 in human glioma cells. Cell Tissue Res 303:27-34 (Pubitemid 32200285)
29. Eriksson B, Oberg K 1999 Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 10(Suppl 2):S31-S38 (Pubitemid 29288528)
30. Wynick D, Anderson JV, Williams SJ, Bloom SR 1989 Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol (Oxf) 30:385-388 (Pubitemid 19110010)
31. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW 2005 Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 28(11 Suppl International):36-42
32. 111In-pentetreotide: is there evidence of somatostatin receptor downregulation? J Nucl Med 47:354-359
33. Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG 2002 Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 146:295-302
34. Froidevaux S, Hintermann E, Török M, Mäcke HR, Beglinger C, Eberle AN 1999 Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 59:3652-3657
35. Anthony CT, Hughey S, Lyons J, Weiss S, Hornick CA, Drouant GJ, Fuselier JA, Coy DH, Murphy WA, Woltering EA 2004 The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs. J Surg Res 119:1-13